Rituximab Prednisone
Rituximab Prednisone 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为DLBCL。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
8 项
已进入 III/IV 期
24 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- University of Rochester
- Dizal Pharmaceuticals
- Zhejiang Cancer Hospital
- Sun Yat-sen University
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- The First Affiliated Hospital with Nanjing Medical University
- Ruijin Hospital
- Mingzhi Zhang
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、Argentina、澳大利亚、Chile、Greece、Israel、意大利、Poland、South Korea、西班牙、中国台湾
正在招募患者的 Rituximab Prednisone 研究
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
I 期 / II 期招募中中国NCT07059650RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
II 期招募中中国NCT06674096Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
I 期 / II 期招募中中国NCT06760039Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
I 期 / II 期招募中中国NCT06829771Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
I 期 / II 期招募中中国NCT04432714The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
III 期招募中中国NCT05018520A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
I 期 / II 期招募中中国NCT06683885A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
II 期 / III 期招募中美国Argentina澳大利亚ChileNCT07634471A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
II 期招募中中国NCT06569485Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
IV 期招募中法国GuadeloupeNCT05898308Pola-ZR2P in Previously Untreated DLBCL
II 期招募中中国NCT06664411Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
II 期招募中中国NCT07499271Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
III 期招募中加拿大NCT06983821Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
不适用招募中中国NCT07778212Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
I 期招募中美国NCT06730542Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
IV 期招募中中国NCT07788456Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
不适用招募中EgyptNCT07057765Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
II 期招募中美国NCT06954805A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
II 期招募中美国NCT05800366A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
III 期招募中美国澳大利亚Brazil加拿大NCT06911502Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
III 期招募中中国NCT06520163A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
III 期招募中美国澳大利亚奥地利比利时NCT06091865A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
II 期招募中美国NCT03758989Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
II 期招募中中国NCT07494565
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。